Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan

International Journal of Cancer

Volumn 123, Issue 7, 2008, Pages 1685-1692

  Lai, Chyong Huey ^a,c   Chao, Angel ^a   Chang, Chee Jen ^b   Chao, Fang Yu ^a   Huang, Huei Jean ^a   Hsueh, Swei ^a   Lin, Cheng Tao ^a   Cheng, Hui Hsin ^a   Huang, Chu Chun ^a   Yang, Jung Erh ^a   Wu, Tzu I ^a   Chou, Hung Hsueh ^a   Chang, Ting Chang ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Clearance; Genotype; Human papillomavirus; Viral load

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGISTRY; CLEARANCE; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; TAIWAN; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS LOAD; WART VIRUS; ALPHAPAPILLOMAVIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; QUESTIONNAIRES; TAIWAN; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 50549088549     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23679     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
3. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, Chao FY, Qiu JT, Hong JH, Chou HH, Chang TC, Chang CJ. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007;120:1999-2006.
6. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8.
7. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
8. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
9. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-6.
10. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-31.
11. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
12. Smith EM, Ritchie JM, Levy BT, Zhang W, Wang D, Haugen TH, Turek LP. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev 2003;27:472-80.
13. Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005;162:668-75.
14. Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramirez M, Villegas M, Schiffman M, Rodriguez AC, Burk RD, Hildesheim M, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006;66:11070-6.
15. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-94.
16. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007;96:1419-24.
17. Aho J, Hankins C, Tremblay C, Forest P, Pourreaux K, Rouah F, Coutlee F. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004;190:46-52.
18. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94:1406-14.
19. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97:129-32.
20. Chao A, Hsu KH, Lai CH, Huang HJ, Hsueh S, Lin SR, Jung SM, Chao FY, Huang SL, Huang CC, Yang JE, Chang TC. Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study. Int J Cancer 2008;122:2835-41.
21. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005;105:905-918.
22. Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, Lin CY, Yan CC, Chou HH, Huang KG, Huang HJ, Wu TI, et al. Comparison between the Hybrid Capture II Test and a SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006;44:1733-9.
23. Chan PK, Yu MM, Cheung TH, To KF, Lo KW, Cheung JL, Tong JH. Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of patients with early stage cervical carcinoma. J Clin Virol 2005;33:201-5.
24. Fujii T, Masumoto N, Saito M, Hirao N, Niimi S, Mukai M, Ono A, Hayashi S, Kubushiro K, Sakai E, Tsukazaki K, Nozawa S. Comparison between in situ hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia. Diagn Mol Pathol 2005;14:103-8.
25. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-90.
26. Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB, Johansson BC, Syrjanen SM. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 2007;16:17-22.
27. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
28. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-17.
29. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
30. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.
31. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16 and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
32. Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, McGoogan E. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005;58:946-50.
33. van den Akker-van Marie ME, van Ballegooijen M, Rozendaal L, Meijer CJ, Habbema JD. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003;89:1830-3.
34. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. J Natl Cancer Inst 2001;286:3106-14.